KAVITA KALRA, M.D.
Hematology & Oncology Physician · BALTIMORE, MD
Individual Active NPI 1063495232
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 584 | 279,538 | $15,086,826 | $5,025,233 | $3,992,403 |
| 2023 | 493 | 160,971 | $19,384,077 | $3,046,174 | $2,425,945 |
| 2022 | 249 | 41,264 | $3,892,977 | $1,060,597 | $846,594 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J1306 | Injection, inclisiran, 1 mg | 80,662 | $12 | $9 |
| J3111 | Injection, romosozumab-aqqg, 1 mg | 45,787 | $11 | $8 |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 15,016 | $22 | $17 |
| J2182 | Injection, mepolizumab, 1 mg | 9,518 | $30 | $24 |
| J2350 | Injection, ocrelizumab, 1 mg | 8,433 | $55 | $44 |
| J0897 | Injection, denosumab, 1 mg | 4,681 | $25 | $20 |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | 3,328 | $8 | $6 |
| 96372 | Injection of drug or substance under skin or into muscle | 1,339 | $15 | $12 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 1,148 | $0 | $0 |
| J9312 | Injection, rituximab, 10 mg | 887 | $76 | $60 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 882 | $0 | $0 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 560 | $0 | $0 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Hematology & Oncology Physician | 207RH0003X | ✓ | D58037 | MD |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Hematology & Oncology Physician providers in Maryland
- NPI 1528680279
- NPI 1528572187
- NPI 1134409923
- NPI 1508085887
- NPI 1104808047
- NPI 1629411558
- NPI 1629865126
- NPI 1508908245
See all Hematology & Oncology Physician providers in Maryland →
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.